Judge puts off approval of Amgen's $762M settlement; Bayer beefs up pension trust by €1B;

@FiercePharma: Lagging Lundbeck cuts its financial outlook for 2013 + 2014, on European sluggishness, R&D costs. More | Follow @FiercePharma

> A federal judge delayed his ruling on Amgen's ($AMGN) proposed $762 million settlement in an off-label marketing case involving its anemia drug Aranesp. Report

> Bayer moved about €1 billion ($1.3 billion) worth of securities to its pension trust fund. Report

> Moody's Investors Service upgraded Merck KGaA to Baa1 with a stable outlook, even as the company's stock fell on disappointing trial data. Report | Report

> A Standard & Poor's report concludes that big drugmakers will find new sources of growth as the patent cliff winds down. Report

Medical Device News

 @FierceMedDev: Nanotech transforms blood tumor cells into viable Dx tool. News | Follow @FierceMedDev

@MarkHFierce: Smith & Newphew vs. ConvaTec over a wound dressing patent issue; ConvaTec won. Report | Follow @MarkHFierce

 @DamianFierce: Privately held CardiacAssist is targeting the heart pump market after getting FDA OK for a pivotal trial. Story | Follow @DamianFierce

> Angel Medical pulls in $27.5M to fuel U.S. heart monitor trial. Article

> Report: Nonvascular ablation use poised to soar. Item

Biotech News

 @FierceBiotech: Oncothyreon routed after Merck KGaA's Stimuvax flops in big PhIII lung cancer trial. Story | Follow @FierceBiotech

@JohnCFierce: Ex-GSK scientists grab $18M, neurosciences portfolio for startup. News | Follow @JohnCFierce

@RyanMFierce: Bristol-Myers' Sigal outshines pharma rivals in R&D chief ranking. (Does Jeremy Levin deserve some credit?) More | Follow @RyanMFierce

> Can Big Pharma sustain a swelling rate of new drug approvals? Article

> Regado backers provide $51M to fuel high-stakes PhIII anticoagulant study. News

> Allon shares collapse as ambitious CNS study ends in disastrous flop. Report

Drug Delivery News

> Helix and Merck terminate topical interferon collaboration. Article

> Langer nanoparticle startup Blend bags $16M funding and new CEO. News

> Unigene's oral bone drug doesn't give women the needle. Story

> Drugs sneak through the skin without patches. Item

Biomarkers News

> Myriad to peruse Sanofi insulin trial samples for biomarker clues. Report

> Merck turns to GE agent to track potential Alzheimer's biomarker. Article

> MIT's nanoparticles make cancer biomarkers more visible. News

> Protein doubles as diagnostic and drug target for blood cancer. Story

> SynapDx snags $6M for autism Dx study. Item

And Finally... Bullying may actually trigger genetic changes that make victims more vulnerable to mental health problems, a study found. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.